This is a working overview of dual agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-15. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
There are a few slightly more common diagnoses such as pulmonary hypoplasia, cryptorchidism, congenital heart defects, tracheoesophageal fistulas, inguinal hernias, cleft palate, and eye abnormalities.
== Prognosis == With treatment, the majority of people with BPD can find relief from distressing symptoms and achieve remission, defined as a consistent relief from symptoms for at least two years. Remission rates are about 50–70% over five years. The remission rate is estimated to be around 50% at ten years, with 93% of people being able to achieve a two-year remission and 86% achieving at least a four-year remission, with a 30% risk of relapse over 10 years. Patient personality can play an important role during the therapeutic process, leading to better clinical outcomes. Recent research has shown that BPD patients undergoing dialectical behavior therapy (DBT) exhibit better clinical outcomes correlated with higher levels of the trait of agreeableness in the patient, compared to patients either low in agreeableness or not being treated with DBT. This association was mediated through the strength of a working alliance between patient and therapist; that is, more agreeable patients developed stronger working alliances with their therapists, which, in turn, led to better clinical outcomes. In addition to recovering from distressing symptoms, people with BPD can also achieve high levels of psychosocial functioning. A longitudinal study tracking the social and work abilities of participants with BPD found that six years after diagnosis, 56% of participants had good function in work and social environments, compared to 26% of participants when they were first diagnosed. Vocational achievement was generally more limited, even compared to those with other personality disorders.
=== Novel technologies and mechanisms of cognitive function === Technologies for imaging brain activity The Sur laboratory developed high resolution two-photon microscopy in the intact mouse brain to show that synapses on visual cortex pyramidal neurons are highly dynamic structures whose form and function can change under the influence of electrical activity. They have continued to develop advanced multi-photon technologies for imaging the calcium activity of cells and their processes across multiple cortical areas and depths. Mechanisms of learning and cognition Combined with cell- and projection-specific manipulations, high-density recordings and computational analyses, these technologies have demonstrated principles of information representation, decisions and action selection in higher (parietal and prefrontal) cortex in mice performing perceptual discrimination and memory-guided decision tasks. The lab has elucidated distinct roles of prefrontal cortex subregions that provide feedback to V1 across behavioral states, demonstrating exquisite specificity of top-down projections in cortical networks. The lab is opening up new ways to address longstanding questions about the neural architecture of cognition. For example, they have shown that pulvinar inputs to prefrontal cortex encode sensory history as a low-dimensional activity manifold that forms a substrate for attention, and modular subsets of prefrontal cortex neurons representing specific functions are computationally recombined across tasks to generate flexible behavior.
=== Skin cell table === The below table identifies the skin cell count and aggregate cell mass estimates for a 70 kg adult male (ICRP-23; ICRP-89, ICRP-110). Tissue mass is defined at 3.3 kg (ICRP-89, ICRP110) and addresses the skin's epidermis, dermis, hair follicles, and glands. The cell data is extracted from 'The Human Cell Count and Cell Size Distribution', Tissue-Table tab in the Supporting Information SO1 Dataset (xlsx). The 1200 record Dataset is supported by extensive references for cell size, cell count, and aggregate cell mass. Detailed data for below cell groups are further subdivided into all the cell types listed in the above sections and categorized by epidermal, dermal, hair follicle, and glandular subcategories in the dataset and on the dataset's graphical website interface. While adipocytes in the hypodermal adipose tissue are treated separately in the ICRP tissue categories, fat content (minus cell-membrane-lipids) resident in the dermal layer (Table-105, ICRP-23) is addressed by the below interstitial-adipocytes in the dermal layer.
Sources: en.wikipedia.org
Additionally, in January 1978, the band appeared as themselves in two episodes of the ABC sitcom What's Happening!!, performing "Echoes of Love," "Little Darlin' (I Need You)", "Black Water", "Takin' It to the Streets", and "Take Me in Your Arms". Performances were done live (versus lip synching to a pre-recorded track), with some overdubs added in post production, notably during Baxter's solo on "Take Me in Your Arms (Rock Me a Little While)," which was lifted from the album version. After almost a decade on the road, and with seven albums to their credit, the Doobies' profile was substantially elevated by the success of their next album, 1978's Minute by Minute. It spent five weeks atop the charts and dominated several radio formats for the better part of two years. McDonald's song "What a Fool Believes", written with Kenny Loggins, was the band's second No. 1 single and earned the songwriting duo (along with producer Ted Templeman) a Grammy Award for Record of the Year. The album won a Grammy for Pop Vocal Performance by a Group and was nominated for Album of the Year. Both "What a Fool Believes" and the title track were nominated for Song of the Year, with "What a Fool Believes" winning the award. Among the other memorable songs on the album are "Here to Love You", "Dependin' On You" (co-written by McDonald and Simmons), "Steamer Lane Breakdown" (a Simmons bluegrass instrumental) and McDonald's "How Do the Fools Survive?" (co-written by Carole Bayer Sager). Nicolette Larson and departed former bandleader Johnston contributed guest vocals on the album.
Like the genus Lactarius, russulas have a distinctive flesh consistency, which is also reflected in the appearance of the gills and stipe, and normally makes them immediately recognizable. They have no trace of a veil (no ring, or veil remnants on the cap). The gills are brittle except in a few cases, and cannot be bent parallel with the cap without breaking. Hence the genus Russula is sometimes known colloquially as "brittle gills". They have splitting gills and do not exude a milky substance at cut surfaces, contrary to the genus Lactarius. Presence of large spherical cells, 'sphaerocysts', in the stipe is an important characteristic feature to distinguish the members of Russulaceae from other mushrooms. In Russula, the stipe breaks like the flesh of an apple, while in most other families it only breaks into fibres. The spore powder varies from white to cream, or even orange. While it is relatively easy to identify a sample mushroom as belonging to this genus, it is a significant challenge to distinguish member species of Russula. This task often requires microscopic characteristics, and subtle subjective distinctions, such as the difference between a mild to bitter and a mild to acrid flavor. Moreover, the exact phylogenetic relationships of these mushrooms have yet to be resolved in the professional mycological community, and may ultimately depend on DNA sequencing analysis. The following characteristics are often important in identifying individual species:
According to Sagan, the first civilization with which humanity would come into contact could be between "1.5 J" and "1.8 K"; a galactic supercivilization would be at the "3 Q" stage, while a federation of galaxies could be at the "4 Z" stage. The information and energy axes are not strictly interdependent, so even a level Z civilization would not have to be Kardashev Type III. Sagan believed that no civilization had yet reached level Z, speculating that so much unique information would exceed that of all the intelligent species in a galactic supercluster, and observing that the universe is not old enough to exchange information effectively over large distances. In 2017, the total amount of information generated on the internet was 26 zettabytes (with an estimated 120 zettabytes in 2023), equivalent to 0.73 R/S on Sagan's combined scale.
== Terminology == The term rheumatism stems from the Late Latin rheumatismus, ultimately from Greek ῥευματίζομαι "to suffer from a flux", with rheum meaning bodily fluids, i.e., any discharge of blood or bodily fluid. Before the 17th century, the joint pain which was thought to be caused by viscous humours seeping into the joints was always referred to as gout, a word adopted in Middle English from Old French gote "a drop; the gout, rheumatism". The English term rheumatism in the current sense has been in use since the late 17th century, as it was believed that chronic joint pain was caused by excessive flow of rheum which means bodily fluids into a joint.
=== Other workup methods === Penile nerves function Tests such as the bulbocavernosus reflex test are used to ascertain whether there is enough nerve sensation in the penis. The physician squeezes the glans (head) of the penis, which immediately causes the anus to contract if nerve function is normal. A physician measures the latency between squeeze and contraction by observing the anal sphincter or by feeling it with a gloved finger in the anus. Nocturnal penile tumescence (NPT) It is normal for a man to have five to six erections during sleep, especially during rapid eye movement (REM). Their absence may indicate a problem with nerve function or blood supply in the penis. There are two methods for measuring changes in penile rigidity and circumference during nocturnal erection: snap gauge and strain gauge. A significant proportion of males who have no sexual dysfunction nonetheless do not have regular nocturnal erections. Penile biothesiometry This test uses electromagnetic vibration to evaluate sensitivity and nerve function in the glans and shaft of the penis. Dynamic infusion cavernosometry (DICC) Technique in which fluid is pumped into the penis at a known rate and pressure. It gives a measurement of the vascular pressure in the corpus cavernosum during an erection. Corpus cavernosometry Cavernosography measurement of the vascular pressure in the corpus cavernosum. Saline is infused under pressure into the corpus cavernosum with a butterfly needle, and the flow rate needed to maintain an erection indicates the degree of venous leakage.
Sources: en.wikipedia.org
These genes encode a variety of well established PIDDosome components and significant signaling proteins, including PIDD1, CRADD, CASP2, p53, and cyclin-dependent kinase inhibitor 1A (CDKN1A, often referred to as p21). They also encompass four proteins not previously associated with PIDDosome signaling: centrosomal protein 20 (CEP20, also known as FOPNL), C2 domain-containing protein 3 (C2CD3), which is involved in centriole elongation, sodium channel and clathrin linker 1 (SCLT1), and ankyrin repeat domain 26 (ANKRD26). The ability of these proteins to inhibit the proliferation of cells overexpressing PLK4 was confirmed through competition assays, underscoring their important functions in cell cycle regulation. Inadequate centrosome clustering resulted in a reduced activation of the PIDDosome, as shown by diminished CASP2 activation and lower p21 levels in RPE-1 cells with PLK4 overexpression and absent ANKRD26. Further experiments, involving both ANKRD26-competent and -deficient RPE-1 cells along with various full-length proteins, mutants lacking specific domains, and non-cleavable variants, demonstrated that PIDD1's recruitment to centrioles is mediated by the interaction between the acidic region of ANKRD26 and the UPA domain of the C-terminal part of PIDD1 (PIDD1-CC), which arises from PIDD1's autoproteolytic processing. Importantly, in the context of inducible PLK4, this interaction was critical for the activation of the PIDDosome and the resulting cell cycle arrest.
He also served as a member of the executive committee of the American Society for Testing and Materials (A.S.T.M.) Committee E-19 on Chromatography (1966–1973); as a foreign member of the executive committee of the (British) Chromatographic Society (1992–1997); and as an executive committee member of the Chromatography Subdivision of the Division of Analytical Chemistry of the American Chemical Society (A.C.S.).
Launched from LC-19 at Cape Kennedy Air Force Station, Florida, Gemini 4 was the first flight to be controlled by the new Mission Control Center at the Manned Spacecraft Center in Houston, Texas, which had to conduct three-shift operations due to the flight's long duration. The broadcast of the launch was itself historic. For the first time an international audience, from 12 European nations, could watch the lift-off on live television via the Early Bird satellite. Press interest, due to the satellite broadcast and the new center in Houston, proved to be so high that NASA had to lease buildings to accommodate the 1,100 print and broadcast journalists who requested accreditation. Flight control shifted from Cape Kennedy to Houston as soon as the vehicle cleared the launch tower. At liftoff, two roll transients caused by misalignment of the Titan first-stage engines occurred; these were quickly corrected by the autopilot. The fuel top-off umbilical failed to detach and was pulled loose when the booster had climbed about 27 feet (8.2 meters). A small oscillation in the pitch and yaw planes resulted from this. Performance of all launch vehicle systems was nearly nominal. Some modifications had been made to the guidance program on Gemini 4's booster to produce a less lofted flight trajectory and a lower altitude at booster engine cut-off (BECO) than on Gemini 3; these were generally successful despite a still somewhat lofted flight path. BECO occurred at T+152 seconds; second-stage engine cut-off (SECO) occurred at T+333 seconds.
May lead to hypoglycemia or diabetes Increased risk of PCOS Increased synthesis of VLDL (hypertriglyceridemia) Hypertension (insulin increases sodium retention by the renal tubules) Coronary Artery Disease (increased insulin damages endothelial cells) Increased risk of cardiovascular disease Weight gain and lethargy (possibly connected to an underactive thyroid) Obesity and hyperinsulinemia have some links with some types of cancer
A unique tetranuclear copper center has been found in nitrous-oxide reductase. Chemical compounds which were developed for treatment of Wilson's disease have been investigated for use in cancer therapy.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.